Physician profile
Kolean Crawford
NPI 1073284642
$5,323.60
in general payments reported to CMS, 2019-2025
52 companies · $915 in 2025
The $915 reported for 2025 was more than what 84% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $386 · 2022: $1,878 · 2023: $1,182 · 2024: $963 · 2025: $915.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,059.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,244.85 | 2021-2025 | |
| Amgen INC. | $397.87 | 2021-2025 | Evenity, Repatha, Otezla |
| Teva Pharmaceuticals USA, INC. | $388.89 | 2021-2024 | Austedo Xr, Austedo |
| Novartis Pharmaceuticals Corporation | $205.76 | 2022-2023 | |
| Novo Nordisk INC | $194.67 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Biogen, INC. | $168.83 | 2021-2023 | Vumerity, Tysabri, Plegridy |
| Exact Sciences Corporation | $158.65 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals Lp | $134.75 | 2024-2025 | Airsupra, Farxiga |
| Biohaven Pharmaceutical Holding Company Ltd. | $131.59 | 2022 | |
| Pfizer INC. | $131.48 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $128.88 | 2023-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $125.99 | 2022-2024 | Mounjaro, Emgality, Zepbound |
| Sk Life Science, INC. | $120.14 | 2022-2023 | |
| Amneal Pharmaceuticals LLC | $119.99 | 2022-2023 | Rytary |
| Genzyme Corporation | $119.50 | 2021-2022 |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kolean Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.